Marzeptacog alfa

Drug Profile

Marzeptacog alfa

Alternative Names: CB 813; CB 813d; Marzeptacog alpha; PF-05280602; PF-5280602; Recombinant Factor VIIa variant (813d) - Pfizer

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Catalyst Biosciences
  • Class Blood coagulation factors; Peptide hydrolases; Recombinant proteins
  • Mechanism of Action Factor VIIa stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haemophilia; Surgical blood loss

Most Recent Events

  • 01 Feb 2017 Pharmacodynamics and pharmacokinetics data from a preclinical in Haemophilia A and B released by Catalyst Biosciences
  • 01 Feb 2017 Catalyst plans phase I/II trial for Haemophilia B
  • 26 Jan 2017 Catalyst plans a phase II/II trial for Haemophilia (9212762; 9210706)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top